4.6 Article

Outcomes and Complications With Off-Label Use of Drug-Eluting Stents Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 1, 期 4, 页码 405-414

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2008.06.005

关键词

drug-eluting stents; off-label indications; percutaneous coronary intervention (PCI)

资金

  1. Cordis Corporation
  2. Boston Scientific Corporation
  3. Possis Medical
  4. Medicines Company

向作者/读者索取更多资源

Objectives This study evaluates outcomes and complications in patients treated with drug-eluting stents (DES) for off-label indications. Background Drug-eluting stents have been effective in randomized trials, but their safety and efficacy for off-label indications has not been well studied. Methods The STENT (Strategic Transcatheter Evaluation of New Therapies) Registry is the largest multicenter U.S. registry evaluating outcomes of DES. Off-label indications included ostial, left main, long, bifurcation, and in-stent restenotic lesions, saphenous vein grafts, chronic total occlusions, small or large vessels, multilesion or multivessel percutaneous coronary interventions, and ST-segment elevation myocardial infarction. Outcomes were adjusted using Cox proportional hazards regression and propensity analyses. Results Drug-eluting stents were used in an off-label manner in 59% of patients. The patients who received off-label treatment were more often male, had a higher incidence of prior infarction and bypass surgery, and lower ejection fractions. Off-label versus on-label use of DES was associated with higher rates of death, myocardial infarction, target vessel revascularization, major adverse cardiac events, and stent thrombosis at 9 months and 2 years. Off-label use of DES compared with off-label use of bare-metal stents (BMS) had lower rates of death, myocardial infarction, target vessel revascularization, and major adverse cardiac events at 9 months and 2 years and lower rates of stent thrombosis at 9 months. Conclusions Off-label use of DES is associated with higher event rates compared with on-label use of DES, which is consistent with a higher risk clinical and lesion profile. However, event rates with off-label use of DES are lower compared with off-label use of BMS. Pending results from randomized trials, our data support the use of DES for off-label indications in selected patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据